India's Leading Healthcare & Pharma Companies 2023

India’s Leading Healthcare & Pharma Companies 2023 | 25 [ EXPERT’S VIEW ] What are the offerings of Sigachi Industries towards pharmaceutical industry? Sigachi specializes in drug delivery systems which ensures inactive ingredients are designed to suit all types of active ingredients for solid oral dosage forms. Sigachi first introduced “Multifunctional Excipients” or all-in-one-excipients to the world and has over 60 types of excipients catering to the entire spectrum of solid and liquid oral dosage forms. Sigachi forayed into the healthcare industry through branded gener i cs and OTC drugs and plans to venture into Intermediates and API segments. What are major USPs of Sigachi Industries? Since incept ion, Sigachi has maintained a level of agi l i ty commensurate to meet the dynamic needs of the formulations industry. Our 60 SKUs of basic and high functional/multifunctional excipients exhibi t company’s inherent key competenc ies . Sigachi has primarily supplied through regu l a ted mar ket s over 60+ countries. Company’s three units are EDQM approved Sigachi Industries Limited Amit Raj Sinha Managing Director & CEO with certification of suitability, demonstratingSigachi’s adherence to regulatory and compliance aspects. We have 18 Drug Master Files (DMF) from the USFDA, and a few DMFs from the Chinese FDA. We offer over 150+ branded generics products as affordable healthcare solutions. The three National Awards from the Ministry of MSME were impetus for us to advance in the pharma-healthcare sector. What are the major milestones of the company? The upcoming expansion of our cellulose-based excipients by over 7,000 MTPA to bring the total capacity to 21,000 MTPA will make us India’s largest player and catapulting us to the top rungs of manufacturers worldwide. Our transition from being suppliers to solution provider was accelerated by the commissioning of full-scale excipient R&D Lab (2014) and the Food Application Lab (2018). Also, subsidiaries in US and UAE have added to the reach of our products. Company’s historic listing on BSE and NSE in 2021 smashed a 13-year-old BSE record with a gain of more than 270% of the listing price. What are the future plans or strategies of Sigachi Industries going forward? We are progressively diversifying our product mix for the pharma, food and nutrition, and healthcare industries as we transform to become a vertically integrated pharma player. Our strategic priorities are defined with the goal of enabl ing “Experience Excellence” for all our stakeholders. T h e s e i n c l ude p r omo t i ng a c ompa n y - w i de f i n a n c i a l template for sustained growth, diversification and de-risking, multilevel transformation of the business, as well as maintaining and strengthening the Sigachi culture of excellence. How does Sigachi Industries prioritize sustainability and environmental considerations? Future self-evaluations will be based on the quadruple bottom l i ne , t hus have embedded sustainability and environment firmly in our operations. To reduce energy and water waste, company audits its operations by tracking consumption across all its verticals. We reuse water from the STPs and ETPs to reduce our emissions footprint and plan further to transition towards alternate fuel and renewable energy, waste recycling, rainwater harvesting, and sourcing of raw materials only from ESG compliant suppliers. Dun & Bradstreet